Autonomic Dysfunction

Categories: Blood diseases, Neuronal diseases

Aliases & Classifications for Autonomic Dysfunction

MalaCards integrated aliases for Autonomic Dysfunction:

Name: Autonomic Dysfunction 53
Autonomic Nervous System Disorders 71
Autonomic Disorder 54


External Ids:

UMLS 71 C1145628

Summaries for Autonomic Dysfunction

NINDS : 53 Dysautonomia refers to a disorder of autonomic nervous system (ANS) function that generally involves failure of the sympathetic or parasympathetic components of the ANS, but dysautonomia involving excessive or overactive ANS actions also can occur. Dysautonomia can be local, as in reflex sympathetic dystrophy, or generalized, as in pure autonomic failure. It can be acute and reversible, as in Guillain-Barre syndrome, or chronic and progressive. Several common conditions such as diabetes and alcoholism can include dysautonomia. Dysautonomia also can occur as a primary condition or in association with degenerative neurological diseases such as Parkinson's disease. Other diseases with generalized, primary dysautonomia include multiple system atrophy and familial dysautonomia. Hallmarks of generalized dysautonomia due to sympathetic failure are impotence (in men) and a fall in blood pressure during standing (orthostatic hypotension). Excessive sympathetic activity can present as hypertension or a rapid pulse rate.

MalaCards based summary : Autonomic Dysfunction, also known as autonomic nervous system disorders, is related to multiple system atrophy 1 and neuronal intranuclear inclusion disease, and has symptoms including seizures, vomiting and tremor. An important gene associated with Autonomic Dysfunction is ECE1 (Endothelin Converting Enzyme 1), and among its related pathways/superpathways are Neuroscience and Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics. The drugs Rotigotine and Granisetron have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and spinal cord, and related phenotypes are behavior/neurological and integument

Wikipedia : 74 Dysautonomia or autonomic dysfunction is a condition in which the autonomic nervous system (ANS) does... more...

Related Diseases for Autonomic Dysfunction

Diseases related to Autonomic Dysfunction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 635)
# Related Disease Score Top Affiliating Genes
1 multiple system atrophy 1 32.2 SNCA DBH
2 neuronal intranuclear inclusion disease 32.1 SNCA NOTCH2NLC
3 neuropathy, hereditary sensory and autonomic, type iib 31.4 SCN9A RETREG1
4 neuropathy, hereditary sensory and autonomic, type iia 31.1 SCN9A RETREG1
5 pure autonomic failure 31.1 SNCA DBH
6 autonomic neuropathy 30.2 SCN9A RETREG1 DBH
7 central hypoventilation syndrome, congenital 29.6 ECE1 DBH
8 rem sleep behavior disorder 29.6 SNCA SLC18A2
9 dopamine beta-hydroxylase deficiency 29.5 SNCA DBH
10 movement disease 29.0 SNCA SLC18A2
11 alcohol dependence 28.6 SNCA SLC18A2 DBH CHRNA3
12 hirschsprung disease, cardiac defects, and autonomic dysfunction 12.8
13 pitt-hopkins syndrome 11.8
14 neuroleptic malignant syndrome 11.7
15 autosomal dominant leukodystrophy with autonomic disease 11.7
16 dysautonomia 11.6
17 lambert-eaton myasthenic syndrome 11.5
18 autonomic nervous system disease 11.5
19 bladder dysfunction, autonomic, with impaired pupillary reflex and secondary cakut 11.4
20 spinocerebellar ataxia 34 11.3
21 spastic paraplegia 2, x-linked 11.3
22 parkinsonism-dystonia, infantile, 2 11.3
23 neuropathy, hereditary sensory and autonomic, type ia 11.1
24 paroxysmal extreme pain disorder 11.1
25 perry syndrome 11.1
26 indifference to pain, congenital, autosomal recessive 11.1
27 parkinson disease 4, autosomal dominant 11.1
28 aromatic l-amino acid decarboxylase deficiency 11.1
29 sudden infant death with dysgenesis of the testes syndrome 11.1
30 neuropathy, hereditary sensory and autonomic, type ic 11.1
31 parkinson disease 5, autosomal dominant 11.1
32 brown-vialetto-van laere syndrome 11.1
33 striatonigral degeneration 11.1
34 brain dopamine-serotonin vesicular transport disease 11.1
35 opsoclonus-myoclonus syndrome 11.1
36 myoclonic encephalopathy of infants 11.1
37 neuropathy 10.5
38 syncope 10.5
39 orthostatic intolerance 10.5
40 guillain-barre syndrome 10.4
41 polyneuropathy 10.4
42 constipation 10.4
43 multiple sclerosis 10.4
44 resting heart rate, variation in 10.4
45 impotence 10.4
46 cardiac conduction defect 10.3
47 sleep apnea 10.3
48 peripheral nervous system disease 10.3
49 migraine with or without aura 1 10.3
50 scleroderma, familial progressive 10.3

Graphical network of the top 20 diseases related to Autonomic Dysfunction:

Diseases related to Autonomic Dysfunction

Symptoms & Phenotypes for Autonomic Dysfunction

UMLS symptoms related to Autonomic Dysfunction:

seizures, vomiting, tremor, back pain, constipation, headache, syncope, diarrhea, mydriasis, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, rectal tenesmus, increased sweating, decrease in appetite, vomiting alone, rectal pain, dry throat, hyperemesis, anal pain, vomiting in newborn, lightheadedness, warm skin, palpitations - fluttering, pounding heart, syncope, effort, blackout - symptom

MGI Mouse Phenotypes related to Autonomic Dysfunction:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.73 CHRNA3 DBH RETREG1 SCN9A SLC18A2 SNCA
2 integument MP:0010771 9.55 DBH ECE1 RETREG1 SCN9A SNCA
3 nervous system MP:0003631 9.5 CHRNA3 DBH ECE1 RETREG1 SCN9A SLC18A2
4 taste/olfaction MP:0005394 8.8 SCN9A SLC18A2 SNCA

Drugs & Therapeutics for Autonomic Dysfunction

Drugs for Autonomic Dysfunction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
Levodopa Approved Phase 4 59-92-7 6047
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Metronidazole Approved Phase 4 443-48-1 4173
Norepinephrine Approved Phase 4 51-41-2 439260
Droxidopa Approved, Investigational Phase 4 23651-95-8 443940
Colchicine Approved Phase 4 64-86-8 2833 6167
Mecamylamine Approved, Investigational Phase 4 60-40-2 4032
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
12 Antiemetics Phase 4
13 Anti-Arrhythmia Agents Phase 4
14 Anti-Bacterial Agents Phase 4
15 Anti-Infective Agents Phase 4
16 Antiparasitic Agents Phase 4
17 Antiprotozoal Agents Phase 4
18 Antiparkinson Agents Phase 4
19 Sympatholytics Phase 4
20 Cholinergic Agents Phase 4
21 Tubulin Modulators Phase 4
22 Antimitotic Agents Phase 4
23 Cholinergic Antagonists Phase 4
24 Hypoglycemic Agents Phase 4
25 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
26 Sodium-Glucose Transporter 2 Inhibitors Phase 4
27 Neurotransmitter Agents Phase 4
28 Dopamine Antagonists Phase 4
29 Dopamine Agents Phase 4
30 Psychotropic Drugs Phase 4
31 Antipsychotic Agents Phase 4
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
Methyldopa Approved Phase 3 555-30-6 38853
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
Carbidopa Approved Phase 3 28860-95-9 34359
Rifaximin Approved, Investigational Phase 3 80621-81-4 6436173 46783403
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
Deferasirox Approved, Investigational Phase 3 201530-41-8 5493381
40 Duloxetine Hydrochloride Phase 2, Phase 3
41 Serotonin and Noradrenaline Reuptake Inhibitors Phase 2, Phase 3
42 alpha-Methyltyrosine Phase 3
43 Aromatic Amino Acid Decarboxylase Inhibitors Phase 3
44 Atomoxetine Hydrochloride Phase 3
45 Gastrointestinal Agents Phase 3
46 Liver Extracts Phase 3
47 Chelating Agents Phase 3
48 Iron Chelating Agents Phase 3
Enalapril Approved, Vet_approved Phase 2 75847-73-3 40466924 5362032
Enalaprilat Approved Phase 2 76420-72-9 6917719

Interventional clinical trials:

(show top 50) (show all 229)
# Name Status NCT ID Phase Drugs
1 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
2 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
3 Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients Unknown status NCT03091881 Phase 4 Granisetron 0.1 MG/ML;Placebos
4 Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
5 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
6 The Study of Heart Rate Variability in Patients With Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
7 Efectividad de Saccharomyces Oulardii Para Reducir Los síntomas Gastrointestinales y Evitar el Sobrecrecimiento Bacteriano en Esclerosis sistémica Completed NCT03692299 Phase 4 Saccharomyces Boulardii Oral Tablet;Metronidazole
8 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
9 Colchicine for Prevention Atrial Fibrillation After Cardiac Surgery in the Early Postoperative Period Recruiting NCT04224545 Phase 4 Colchicine;Placebo
10 Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis Recruiting NCT03914677 Phase 4 Mecamylamine Oral Tablet
11 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Not yet recruiting NCT04193566 Phase 4 Forxiga
12 Risperidone and Zotepine in the Treatment of Delirium Terminated NCT00622011 Phase 4 Risperidone and Zotepine for delirium
13 Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
14 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT02427464 Phase 3
15 Effects of Escitalopram vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control Completed NCT00215228 Phase 2, Phase 3 duloxetine vs. escitalopram
16 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00782340 Phase 3 Placebo;Droxidopa
17 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00633880 Phase 3 Placebo;Droxidopa
18 An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension Completed NCT00738062 Phase 3 Droxidopa;Placebo
19 Gut Microbiota Alteration and Improvement of Ataxia in Patients of Multiple System Atrophy Treating With Tllsh2910 - a Randomized, Placebo-controlled, Double-blinded, Cross-over, Single-center Clinical Trial Recruiting NCT03901638 Phase 3 Tllsh2910;Placebo
20 Comparative Efficacy of Platelet Rich Plasma Injection and Dry Needling in Management of Trigger Points in Masseter Muscle in Myofascial Pain Syndrome Patients Recruiting NCT04286880 Phase 3
21 Treatment of Hypotensive Patients Having a Unique Pattern of Autonomic Symptoms Enrolling by invitation NCT00581477 Phase 3 droxidopa;placebo;alpha-methyldopa;carbidopa;metyrosine;levodopa;atomoxetine;metoclopramide
22 Mechanisms, Safety and Efficacy of Optimising Pacemaker Heart Rate for Contractility: Effects on Walk Time, Cardiac Remodelling and Quality of Life Not yet recruiting NCT04201015 Phase 2, Phase 3
23 Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients Not yet recruiting NCT04244877 Phase 3 Rifaximin
24 Clinical Importance of Treating Iron Overload in Sickle Cell Disease Terminated NCT00981370 Phase 3 deferasirox
25 Evaluation à Six Mois du système de dénervation rénale Chez Les Patients Atteints d'Insuffisance Cardiaque Unknown status NCT02471729 Phase 1, Phase 2
26 The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy Unknown status NCT00281502 Phase 2 Rifaximin (drug)
27 Left Cardiac Sympathetic Denervation (LCSD) for Cardiomyopathy Feasibility Pilot Study Unknown status NCT03071653 Phase 2
28 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins Completed NCT00750867 Phase 2 intravenous immunoglobulin (IVIg)
29 A Phase I/II, Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Patients With Painful Diabetic Peripheral Neuropathy Completed NCT01002235 Phase 1, Phase 2
30 A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome Completed NCT02715115 Phase 2 NNZ-2566;Placebo
31 A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome Completed NCT01703533 Phase 2 NNZ-2566;Placebo
32 Daily Incorporation of Blueberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension. Completed NCT01686282 Phase 2
33 A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT01475786 Phase 2
34 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Three Doses of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Completed NCT00229437 Phase 2 TAK-128;TAK-128;TAK-128;Placebo
35 Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure? Completed NCT00291720 Phase 2 Spironolactone;Placebo
36 A Phase 1 Clinical Study to Assess Safety and Efficacy of Oral Fingolimod (FTY720) in Children With Rett Syndrome. Completed NCT02061137 Phase 1, Phase 2 fingolimod (FTY720)
37 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying Completed NCT01602549 Phase 2 GSK962040 (25 mg tablet);Placebo
38 A Phase II, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Clinical Benefit and Safety of Droxidopa in Patients With Intradialytic Hypotension Completed NCT00657046 Phase 2 Droxidopa;Placebo
39 Effects of Oral L-citrulline/L-arginine in Watermelon on Central Blood Pressure and Arterial Stiffness in Individuals With Obesity-related High Blood Pressure Completed NCT01185041 Phase 1, Phase 2
40 Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome Completed NCT01607073 Phase 2 Verapamil
41 Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease Completed NCT03865121 Phase 2 Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)
42 A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease Completed NCT02818777 Phase 2 cannabidiol
43 Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. Recruiting NCT03137537 Phase 2 Ivabradine;Placebo Oral Tablet
44 The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes Recruiting NCT03426085 Phase 2 Liraglutide 6 mg Solution for Injection
45 A Double-Blind, Randomized, Placebo-Controlled Trial To Evaluate The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Recruiting NCT02915263 Phase 2 IGIV-C;0.9% Sodium Chloride
46 A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease Recruiting NCT03582137 Phase 2 Cannabidiol
47 The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease Recruiting NCT03775096 Phase 2 Carvedilol
48 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Active, not recruiting NCT02458690 Phase 2 Antidepressant Medications
49 Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia Not yet recruiting NCT04405596 Phase 1, Phase 2 Ambroxol Hydrochloride
50 Controlled Trial of 3,4-Diaminopyridine in LEMS Terminated NCT02090725 Phase 2 3-4 Diaminopyridine

Search NIH Clinical Center for Autonomic Dysfunction

Genetic Tests for Autonomic Dysfunction

Anatomical Context for Autonomic Dysfunction

MalaCards organs/tissues related to Autonomic Dysfunction:

Heart, Testes, Spinal Cord, Brain, Liver, Skin, Kidney

Publications for Autonomic Dysfunction

Articles related to Autonomic Dysfunction:

(show top 50) (show all 5929)
# Title Authors PMID Year
Exposure to acrylamide and reduced heart rate variability: The mediating role of transforming growth factor-β. 61
32339852 2020
Determining energy requirement and evaluating energy expenditure in neurological diseases. 61
30289025 2020
Autonomic dysfunction, cardio-pulmonary exercise testing and masked heart failure with preserved ejection fraction in non-severe chronic obstructive pulmonary disease. 61
32073740 2020
Cardiac autonomic dysfunction in survivors of childhood acute lymphoblastic leukemia: The St. Jude Lifetime Cohort Study. 61
32383821 2020
Chemogenetic activation of intracardiac cholinergic neurons improves cardiac function in pressure overload-induced heart failure. 61
32412778 2020
Treatment induced neuropathy of diabetes. 61
32247944 2020
Brain Responses in CFS and TMD to Autonomic Challenges: An Exploratory fMRI Study. 61
31461628 2020
[Autonomic dysfunction in the patient with neurodegenerative disease]. 61
32224047 2020
MRI and pathology correlations in the medulla in SUDEP: A post-mortem study. 61
32559314 2020
Acetylcholinesterase inhibition prevents alterations in cardiovascular autonomic control and gastric motility in L-NAME-induced hypertensive rats. 61
32504752 2020
Neuregulin‑1: An underlying protective force of cardiac dysfunction in sepsis (Review). 61
32236630 2020
Spinal cord injury leads to atrophy in pelvic ganglia neurons. 61
32109447 2020
Cardiac autonomic tone, plasma BDNF levels and paroxetine response in newly diagnosed patients of generalised anxiety disorder. 61
32022607 2020
First Bite Syndrome Following Rhytidectomy: A Case Report. 61
32567395 2020
MPTP-Induced Impairment of Cardiovascular Function. 61
32198706 2020
Improvements in Heart Rate Variability in Women with Obesity: Short-term Effects of Sleeve Gastrectomy. 61
32488743 2020
Effect of Yoga Therapy on Disease Activity, Inflammatory Markers, and Heart Rate Variability in Patients with Rheumatoid Arthritis. 61
32326727 2020
Higher Anxiety Is Associated with Lower Cardiovascular Autonomic Function in Female Twins. 61
32539904 2020
Gastrointestinal motility evaluation in children with orthostatic intolerance: Mayo Clinic experience. 61
32483845 2020
Dysautonomia Is Linked to Striatal Dopamine Deficits and Regional Cerebral Perfusion in Early Parkinson Disease. 61
32520498 2020
[A case of paraneoplastic sensory neuronopathy with anti-Hu antibody associated with large cell neuroendocrine carcinoma of the endometrium]. 61
32435048 2020
Prognostic Value of Heart Rate Reserve in Patients with Permanent Atrial Fibrillation during Dipyridamole Stress Echocardiography. 61
32273056 2020
Autonomic Testing Profiles in Scans without Evidence of Dopaminergic Deficit (SWEDD). 61
32538867 2020
A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors. 61
32247028 2020
Oral administration of Lactobacillus fermentum post-weaning improves the lipid profile and autonomic dysfunction in rat offspring exposed to maternal dyslipidemia. 61
32524104 2020
Correction: Autonomic Dysfunction is Associated with Increased Cardiometabolic Risk in Patients with Childhood-Onset Craniopharyngioma. 61
32544969 2020
Autonomic Dysfunction is Associated with Increased Cardiometabolic Risk in Patients with Childhood-Onset Craniopharyngioma. 61
32512610 2020
Skin temperature variability is an independent predictor of survival in patients with cirrhosis. 61
32562383 2020
Posterior reversible encephalopathy syndrome associated with Guillain-Barré syndrome: Case report and clinical management considerations. 61
32289176 2020
Posterior reversible encephalopathy and Guillain-Barré syndrome: which came first, the chicken or the egg? A review of literature. 61
32506357 2020
Autonomic dysfunction and phenoconversion in idiopathic REM sleep behavior disorder. 61
32193800 2020
Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. 61
31971444 2020
Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report. 61
32560740 2020
Systemic Blood Pressure Variation During a 12-Hour Exposure to Normobaric Hypoxia (4500 m). 61
32186921 2020
Impact of depressive symptoms on self-perceived severity of autonomic dysfunction in multiple system atrophy: relevance for patient-reported outcomes in clinical trials. 61
32246226 2020
Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. 61
32087288 2020
Central autonomic dysfunction in multiple system atrophy: can we measure it with MRI? 61
32418031 2020
Diagnosing multiple system atrophy at the prodromal stage. 61
32232688 2020
Influence of disease severity and cardiac autonomic tone on ventricular repolarization and dispersion in electrocardiographic assessment of patients with systemic lupus erythematosus. 61
32486933 2020
Response to: migraine symptoms and the role of the autonomic dysfunction. 61
32498130 2020
Anti-N-methyl-D-aspartate Receptor Encephalitis: a Rare Complication of Ovarian Teratoma. 61
32567259 2020
Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease. 61
31848771 2020
Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy. 61
32232748 2020
Cardiac autonomic modulation in drug-resistant epilepsy patients after vagus nerve stimulation therapy. 61
32557527 2020
Both Prediabetes and Type 2 Diabetes Are Associated With Lower Heart Rate Variability: The Maastricht Study. 61
32161051 2020
Heart rate variability in the course of chemotherapy and haematopoietic stem cell transplantation for peadiatric patients with haematological malignancies. 61
32468969 2020
Clinical Impact of Deep Brain Stimulation on the Autonomic System in Patients with Parkinson's Disease. 61
32373653 2020
Parasympathetic activity as a potential biomarker of negative symptoms in patients with schizophrenia. 61
32452616 2020
Autonomic dysfunction and sudden death in patients with Rett syndrome: a systematic review 61
31702122 2020
Advance in the understanding of vasovagal syncope in children and adolescents. 61
32405708 2020

Variations for Autonomic Dysfunction

Expression for Autonomic Dysfunction

Search GEO for disease gene expression data for Autonomic Dysfunction.

Pathways for Autonomic Dysfunction

Pathways related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.87 SNCA SCN9A DBH
Show member pathways
11.26 SLC18A2 CHRNA3
3 10.32 SLC18A2 DBH
Show member pathways
9.98 SLC18A2 DBH

GO Terms for Autonomic Dysfunction

Cellular components related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synaptic vesicle membrane GO:0030672 8.96 SNCA SLC18A2
2 terminal bouton GO:0043195 8.62 SNCA SLC18A2

Biological processes related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to toxic substance GO:0009636 9.43 SLC18A2 SCN9A
2 post-embryonic development GO:0009791 9.4 SLC18A2 SCN9A
3 excitatory postsynaptic potential GO:0060079 9.37 SNCA CHRNA3
4 sensory perception of pain GO:0019233 9.32 SCN9A RETREG1
5 response to amphetamine GO:0001975 9.26 SLC18A2 DBH
6 positive regulation of receptor recycling GO:0001921 9.16 SNCA ECE1
7 locomotory behavior GO:0007626 9.13 SLC18A2 DBH CHRNA3
8 chemical synaptic transmission GO:0007268 8.92 SNCA SLC18A2 DBH CHRNA3

Molecular functions related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 8.62 SNCA DBH

Sources for Autonomic Dysfunction

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....